Successful treatment of anti-factor H antibody-associated atypical hemolytic uremic syndrome
Anti-complement factor H (CFH) autoantibody (Ab)-associated atypical hemolytic uremic syndrome (aHUS) has a poor prognosis in terms of frequent relapses. Although eculizumab is an effective treatment for this type of aHUS, the method of eculizumab discontinuation is not yet established. Herein, we r...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
| Series: | Indian Journal of Nephrology |
| Subjects: | |
| Online Access: | http://www.indianjnephrol.org/article.asp?issn=0971-4065;year=2020;volume=30;issue=1;spage=35;epage=38;aulast=Kise |